CompletedNCT00095524
Weight change with aripiprazole or olanzapine in schizophrenia
About this title
Read the official source — NCT00095524Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Brazil
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00095524
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Anaheim, United States · Cerritos, United States
29 more locations
- Garden Grove, United States
- National City, United States
- San Diego, United States
- New Britain, United States
- North Miami, United States
- Augusta, United States
- Macon, United States
- Hoffman Estates, United States
- Louisville, United States
- Glen Burnie, United States
- Haverhill, United States
- Worcester, United States
- Minneapolis, United States
- Brooklyn, United States
- Nashville, United States
- Austin, United States
- Dallas, United States
- DeSoto, United States
- San Antonio, United States
- Wauwatosa, United States
- Goibnia, Brazil
- Belo Horizonte, Brazil
- Rio de Janeiro, Brazil
- Porto Alegre, Brazil
- Botucatu, Brazil
- Sao Paulo - Sp, Brazil
- São Paulo, Brazil
- Exeter, United Kingdom
- Birmingham, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 65 years.
